secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2025-06-25T23:59:59+00:00
Accession:  0001628280-25-032959
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid sells future ganaxolone royalties to Immedica for $7.0M cash
-----------------------------------------------------------------

- Immedica pays $7.0M to acquire 100% of Ovid's royalty rights on ganaxolone sales outside China.
- Ovid recorded ~$566K in ganaxolone royalty revenue in 2024; deal provides non-dilutive funding.
- Immedica also obtains additional ganaxolone IP rights and assumes future IP costs.
- Transaction expands Immedica's control of ganaxolone; no impact on Ovid's pipeline.
- Amended license expected within six months to broaden field and territory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025032959/0001628280-25-032959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828025032959/ovid-20250625.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-032959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer